5 Great Stocks For Your New ISA!

Now that the ISA limit has increased, here are 5 top stocks to get you started.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

_ISA1

On Tuesday (1st July) the New ISA came into existence. The New ISA has a limit of £15,000, which is a substantial increase from the £11,880 allowed in the previous Stocks & Shares ISA. So it only seems appropriate to discuss five shares that could prove to be winning investments over the medium term.

BP

After a number of difficult years following the Deepwater Horizon tragedy in 2010, BP (LSE: BP) has steadily reversed much of the share price fall. Indeed, at current levels it appears to offer investors great value for money, with shares in the company trading on a price to earnings (P/E) ratio of just 10.7. This compares favourably to the FTSE 100 P/E of 13.9 and, in addition, BP offers investors a yield of 4.6%. Certainly, bottom-line growth may prove elusive, but there could be scope for an increase in the P/E ratio to make up for it.

GlaxoSmithKline

Despite being in the news of late for all the wrong reasons, GlaxoSmithKline (LSE: GSK) continues to offer a compelling medium term investment case. Its drug pipeline offers a potent mixture of diversity and exceptional peak sales potential, while shares in the company offer a yield of 5.2%. In addition, GlaxoSmithKline’s dividends per share are set to grow by 2.8% next year, while earnings per share (EPS) are forecast to be 9% higher next year. The best bit is that due to the front-page developments in China, shares in GlaxoSmithKline trade on a P/E of just 15.2, which compares favourably to most of its sector peers.

Vodafone

Although Vodafone (LSE: VOD) may no longer be the most stable of companies due to its significant exposure to the Eurozone (where the economy continues to offer only anaemic levels of growth), the company has significant long term potential. That’s because its strategy of buying undervalued assets is a sound one and, while investors are waiting for them to come good, Vodafone rewards them with a current dividend yield of 5.8%, which is above and beyond the FTSE 100 yield of 3.4%.

National Grid

With question marks being raised regarding whether consumers can afford to pay their share of the cost to update the UK’s ageing infrastructure, it is not wholly unlikely that National Grid (LSE: NG) may have to increase its capital expenditure. However, this shouldn’t be too much of a problem, as a £3.2 billion rights issue in 2010 left the company in better financial shape. As ever a strong yield of 5.1% makes National Grid a very appealing income play.

British American Tobacco

Although the sustainability of continual price rises in response to falling cigarette volumes has been brought into question recently, British American Tobacco (LSE: BATS) could be a major winner from the E-Cigarette revolution. That’s because it has taken the development seriously from the outset and has its own brand, Vype, through which to benefit from increased sales in what is already a $1 billion industry. In the meantime, a yield of 4.1% remains attractive.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Peter owns shares in BP, GlaxoSmithKline and National Grid. The Motley Fool has recommended GlaxoSmithKline.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »